Researchers are looking for people with motor neuron disease (MND), such as ALS (amyotrophic lateral sclerosis), to participate in a phase 2 clinical trial to evaluate the safety and effectiveness of the investigational drug FLX-787-ODT.

FLX-787-ODT, under development by Flex Pharma, is taken in tablet form and is designed to reduce muscle cramps in adults with MND.

Trial length is approximately three months, during which participants will visit with study investigators five times. For the duration of the study, participants will record muscle cramp frequency in an e-diary.

In order to be eligible to participate, individuals must be at least 18 years old with a documented diagnosis of MND, such as ALS; have a slow vital capacity of at least 50 percent predicted value; be able to walk unassisted or using an assistive device; be able to communicate verbally without difficulty and meet additional criteria.

The trial is taking place at 15 study sites across the United States, and support for travel costs may be available.

To learn more about this trial, visit the trial website.